We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
A randomized phase 2 study on demeclocycline in patients with mild-to-moderate COVID-19.
- Authors
Iwahori, Kota; Nii, Takuro; Yamaguchi, Norihiko; Kawasaki, Takahiro; Okamura, Satomi; Hashimoto, Kazuki; Matsuki, Takanori; Tsujino, Kazuyuki; Miki, Keisuke; Osa, Akio; Goya, Sho; Abe, Kinya; Mori, Masahide; Takeda, Yoshito; Yamada, Tomomi; Kida, Hiroshi; Kumanogoh, Atsushi
- Abstract
Tetracyclines exhibit anti-viral, anti-inflammatory, and immunomodulatory activities via various mechanisms. The present study investigated the efficacy and safety of demeclocycline in patients hospitalized with mild-to-moderate COVID-19 via an open-label, multicenter, parallel-group, randomized controlled phase 2 trial. Primary and secondary outcomes included changes from baseline (day 1, before the study treatment) in lymphocytes, cytokines, and SARS-CoV-2 RNA on day 8. Seven, seven, and six patients in the control, demeclocycline 150 mg daily, and demeclocycline 300 mg daily groups, respectively, were included in the modified intention-to-treat population that was followed until day 29. A significant change of 191.3/μL in the number of CD4+ T cells from day 1 to day 8 was observed in the demeclocycline 150 mg group (95% CI 5.1/μL–377.6/μL) (p = 0.023), whereas that in the control group was 47.8/μL (95% CI − 151.2/μL to 246.8/μL), which was not significant (p = 0.271). The change rates of CD4+ T cells negatively correlated with those of IL-6 in the demeclocycline-treated groups (R = − 0.807, p = 0.009). All treatment-emergent adverse events were of mild-to-moderate severity. The present results indicate that the treatment of mild-to-moderate COVID-19 patients with demeclocycline elicits immune responses conducive to recovery from COVID-19 with good tolerability. Trial registration: This study was registered with the Japan Registry of Clinical Trials (Trial registration number: jRCTs051200049; Date of the first registration: 26/08/2020).
- Subjects
COVID-19; COVID-19 treatment; PATIENT safety
- Publication
Scientific Reports, 2023, Vol 13, Issue 1, p1
- ISSN
2045-2322
- Publication type
Article
- DOI
10.1038/s41598-023-41051-2